

Section B: New Uses and Formulations of Known Compounds

Groups of related applications and joint applicants are shown in shaded boxes

US20020077347	Abbott (US)	Protein tyrosine phosphatase inhibitors. Abbott is investigating protein tyrosine phosphatase (PTP) 1B inhibitors for the potential treatment of diabetes; preclinical. This application probably relates to WO0218363.
WO0248120	Ajinomoto (JP)	Crystals of oxazepine derivatives. Useful as calcium channel blockers, for treatment of gastric conditions. <i>See</i> WO0040570, WO9733885, WO0117980.
WO0248169	Akzo (NL)	14(15)-unsaturated 15- and/or 16- substituted androgens with mixed androgen-progestational profile.
WO0248171	Akzo (NL)	Methylene steroids as androgens. With a β -oriented, annellated cyclopropyl group which includes C atoms 16 and 17 of the steroid skeleton, <i>ie</i> a 16,17 β -methylene moiety.
WO0247712	Amylin (US)	Peptide YY and peptide YY agonists for treatment of metabolic disorders, <i>eg</i> obesity and diabetes. Amylin are also developing AC-2993, phase III, a glucagon-like peptide 1 agonist, for treatment of diabetes. One inventor previously associated with Ligand Pharmaceutical.
WO0247701	AngioLab (KR)	Anti-angiogenic and matrix metalloproteinase inhibitory composition with Melissa leaf (<i>Melissa officinalis</i> , lemon balm) extract.
EP1214946	Archimedes Technol (US)	MRI-imaging malignant tumors using carbon 13. Inventor also associated with Univ California San Diego.
US20020076434	Aronex (US)	Liposomal retinoid therapy in hormone refractory prostate cancer. Aronex was acquired by Antigenics, which is continuing research in liposomal delivery.
WO0247493	Aventis Pharm (GB)	Health-promoting composition. With several compounds from a long list of vitamins and similar compounds. Inventor apparently associated with Accelerated Learning Systems.
WO0247604	Aventis Pharm (FR)	Use of chalcone class compounds for inhibiting tumoral mass vascularization.
WO0247696	Aventis Pharm (DE)	Treatment of osteoarthritis with low molecular heparin. Use of low molecular heparin for diseases involving increased activity of a matrix-metalloproteinases: neutrophilic collagenase, aggrecanase, hADAMTSl or gelatine A. <i>See</i> enoxaparin sodium, RPR, launched.